Summit Therapeutics
Stock Forecast, Prediction & Price Target
Summit Therapeutics (SMMT) stock Price Target by analysts
$27.5
Potential upside: 7.58%
Summit Therapeutics price prediction
What is Summit Therapeutics stock analysts` prediction?
Summit Therapeutics stock forecast: Based on 2 Wall Street analysts` predicted price targets for Summit Therapeutics in the last 3 months, the avarage price target is $27.5, with a high forecast of $NaN. The average price target represents a 7.58% change from the last price of $25.56.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Summit Therapeutics stock Price Target by analysts
Full breakdown of analysts given Summit Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Reni Benjamin JMP Securities | 0% 0/1 | 11 months ago | $32 25.19% upside | $19.96 | StreetInsider | Previous targets (0) |
Yigal Nochomovitz Summit Redstone Partners | 0% 0/1 | about 1 year ago | $23 -10.01% downside | $20.89 | StreetInsider | Previous targets (0) |
Brad Canino Stifel Nicolaus | 0% 0/3 | about 1 year ago | $40 56.49% upside | $24 | StreetInsider | Previous targets (2) |
Mitchell Kapoor H.C. Wainwright | 0% 0/1 | about 1 year ago | $45 76.05% upside | $31.93 | TheFly | Previous targets (0) |
Brad Canino Stifel Nicolaus | 0% 0/3 | over 1 year ago | $14 -45.22% downside | $8.69 | StreetInsider | Previous targets (2) |
Brad Canino Stifel Nicolaus | 0% 0/3 | over 1 year ago | $8 -68.70% downside | $3.28 | StreetInsider | Previous targets (2) |
Summit Therapeutics Financial Estimates
Summit Therapeutics Revenue Estimates
Summit Therapeutics EBITDA Estimates
Summit Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $1.80M N/A | $704.29K -61.06% | $0 -100% | Avg: $33.70M Low: $33.70M High: $33.70M avg. 0% | Avg: $12.63M Low: $12.63M High: $12.63M avg. -62.52% | Avg: $89.85M Low: $89.85M High: $89.85M avg. 611.43% | Avg: $416.17M Low: $416.17M High: $416.17M avg. 363.15% |
Net Income
% change YoY
| $-86.14M N/A | $-74.38M 13.65% | $-614.92M -726.72% | Avg: $-140.75M Low: $-140.75M High: $-140.75M avg. 77.10% | Avg: $-173.95M Low: $-173.95M High: $-173.95M avg. -23.58% | Avg: $-234.43M Low: $-234.43M High: $-234.43M avg. -34.77% | Avg: $-97.68M Low: $-97.68M High: $-97.68M avg. 58.33% |
EBITDA
% change YoY
| $-86.18M N/A | $-60.80M 29.45% | $1.00M 101.64% | Avg: $-20.22M Low: $-20.22M High: $-20.22M avg. -2120.04% | Avg: $-7.57M Low: $-7.57M High: $-7.57M avg. 62.52% | Avg: $-53.91M Low: $-53.91M High: $-53.91M avg. -611.43% | Avg: $-249.70M Low: $-249.70M High: $-249.70M avg. -363.15% |
EPS
% change YoY
| -$0.93 N/A | -$0.38 59.13% | -$0.99 -160.52% | Avg: -$0.23 Low: -$0.23 High: -$0.23 avg. 77.05% | Avg: -$0.28 Low: -$0.28 High: -$0.28 avg. -23.58% | Avg: -$0.38 Low: -$0.38 High: -$0.38 avg. -34.77% | Avg: -$0.16 Low: -$0.16 High: -$0.16 avg. 58.33% |
Operating Expenses
% change YoY
| $87.99M N/A | $64.28M -26.94% | $87.68M 36.40% | Avg: $600.13M Low: $600.13M High: $600.13M avg. 584.41% | Avg: $224.91M Low: $224.91M High: $224.91M avg. -62.52% | Avg: $1.60B Low: $1.60B High: $1.60B avg. 611.43% | Avg: $7.41B Low: $7.41B High: $7.41B avg. 363.15% |
FAQ
What is Summit Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 19.27% in 2025-2028.
We have gathered data from 1 analysts. Their low estimate is -140.75M, average is -140.75M and high is -140.75M.
What is Summit Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 228.01% in 2025-2028.
We have gathered data from 1 analysts. Their low revenue estimate is $33.70M, average is $33.70M and high is $33.70M.
What is Summit Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 19.25% in 2025-2028.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$0.23, average is -$0.23 and high is $-0.22.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Summit Therapeutics stock. The most successful analyst is Reni Benjamin.